Bovine Tuberculosis Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Bovine Tuberculosis Diagnosis Market is projected to expand from USD 782.12 Million in 2025 to USD 1.06 billion by 2031, registering a CAGR of 5.27%. This sector involves veterinary protocols and assays, including tuberculin skin tests and gamma-interferon detection, used to confirm Mycobacterium bovis infections in cattle. Growth is largely underpinned by strict government-mandated eradication schemes aimed at reducing zoonotic threats and adhering to international trade rules that demand disease-free certification for exports. These regulatory requirements necessitate continuous herd testing to avert the economic damages linked to widespread outbreaks.

Nevertheless, the market encounters a major obstacle due to persistent infection reservoirs in wildlife, which hampers eradication progress and demands repeated, expensive screening. This challenge is highlighted by recent statistics demonstrating the severity of the problem despite control efforts. For example, NFU Cymru reported in 2025 that over 13,000 cattle were slaughtered in Wales throughout 2024 because of bovine tuberculosis, representing a 27% rise from the prior year. Such figures underscore the continuing struggle of disease management, which places a strain on resources and restricts broader market efficiency.

Market Drivers

The enforcement of mandatory government eradication and surveillance initiatives serves as the primary engine for market expansion, as regulatory authorities impose rigorous testing standards. These programs necessitate frequent herd screening, thereby guaranteeing a steady demand for diagnostic consumables. The magnitude of this effort is reflected in the high testing volumes needed for compliance; for instance, the Department for Environment, Food & Rural Affairs reported that over 7.2 million cattle tests were performed in England in 2025. This undertaking is supported by substantial public financing, as evidenced by the Department of Agriculture, Food and the Marine's 'Quarter 3 2025 Bovine TB Disease Trends and Expenditure' report, which noted that Irish government spending on the bovine TB eradication program reached €79.4 million by the third quarter of 2025, a 20% year-on-year increase.

Furthermore, technological progress in molecular and rapid diagnostic assays is transforming the market by overcoming the constraints of conventional methods. Innovations such as the Detect Infected among Vaccinated Animals (DIVA) skin test are pivotal, allowing for the distinction between infected and vaccinated cattle. These advanced diagnostics are quickly transitioning from research phases to practical deployment. According to the Animal and Plant Health Agency's 'Cattle Vaccine Project' announcement in October 2025, Phase 3 field trials for the companion DIVA skin test were initiated, involving the testing of at least 750 animals. Such developments improve diagnostic precision and bolster the strategic objective of total eradication, steering the market toward high-accuracy testing solutions.

Market Challenges

A significant hurdle for the Global Bovine Tuberculosis Diagnosis Market is the endurance of infection reservoirs within wildlife populations. This biological reality fuels a continuous cycle of re-infection, leaving cattle herds susceptible to re-contamination from local vectors like badgers or deer even after rigorous testing and clearance. This persistent threat diminishes the efficacy of standard test-and-slaughter protocols, compelling the industry to prioritize reactive crisis management over proactive market growth. Consequently, the unpredictability of outbreaks driven by wildlife places a financial strain on the livestock sector, restricting the capital available for implementing comprehensive diagnostic testing strategies.

The severity of this economic pressure is highlighted by recent industry statistics. As reported by the Ulster Farmers' Union, the annual herd incidence rate of bovine tuberculosis in Northern Ireland climbed to over 10.4 percent in 2024, a rise largely attributed to wildlife transmission dynamics. Such high incidence rates demonstrate how the failure to manage wildlife reservoirs prolongs the disease's presence, resulting in a volatile market landscape that impedes consistent growth and compromises the overall efficiency of global diagnostic measures.

Market Trends

A crucial shift in diagnostic focus is the expansion of wildlife reservoir surveillance and monitoring, which extends beyond cattle-centric protocols to tackle persistent infections in environmental vectors. Veterinary authorities are increasingly utilizing forensic testing on wildlife, such as badgers, to trace disease transmission routes and assess vaccination effectiveness. This active surveillance fosters a specialized market niche for post-mortem diagnostic kits and rapid field sampling tools tailored for non-bovine species, facilitating more precise biosecurity measures. For example, the Irish Farmers Journal reported in May 2025 that the Department of Agriculture, Environment and Rural Affairs (DAERA) tested 465 badger carcasses in Northern Ireland during 2024 as part of an intensified roadside surveillance project to monitor disease reservoirs.

Concurrently, the transition from tuberculin skin tests to molecular diagnostic assays is revolutionizing the speed and accuracy of disease confirmation. Laboratories are steadily substituting slow bacterial cultures with polymerase chain reaction (PCR) and Whole Genome Sequencing (WGS), technologies that offer rapid identification of Mycobacterium bovis strains and enable exact epidemiological tracing. This technological progression significantly shortens the duration herds spend under movement restrictions and aids strategic eradication by pinpointing local infection clusters with genomic accuracy. As noted in the Animal and Plant Health Agency's 'Bovine tuberculosis in England in 2024' report released in September 2025, Whole Genome Sequencing analysis was successfully performed for 888 new herd incidents where officially TB-free status was withdrawn, highlighting the integration of advanced genomics into routine disease management.

Key Players Profiled in the Bovine Tuberculosis Diagnosis Market

• IDEXX Laboratories, Inc.
• PBD Biotech Ltd.
• Zoetis Inc.
• Innovative Diagnostics SAS
• Thermo Fisher Scientific Inc.
• Enfer Group
• AsureQuality Australia Pty Ltd.
• Bio-Rad Laboratories, Inc.
• Bionote USA Inc.
• Neogen Corporation

Report Scope

In this report, the Global Bovine Tuberculosis Diagnosis Market has been segmented into the following categories:

Bovine Tuberculosis Diagnosis Market, by Tests:

• Molecular Diagnostic Tests
• Serological Tests
• Traditional Tests

Bovine Tuberculosis Diagnosis Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bovine Tuberculosis Diagnosis Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.